<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205956</url>
  </required_header>
  <id_info>
    <org_study_id>009</org_study_id>
    <nct_id>NCT03205956</nct_id>
  </id_info>
  <brief_title>Measuring Parkinson's Disease Progression</brief_title>
  <acronym>MPDP</acronym>
  <official_title>Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kevin J. Black, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Measuring Parkinson's Disease Progression study aims to use MRI scans and a controlled&#xD;
      dose of levodopa to find a biomarker (objective measurement) of Parkinson's disease (PD).&#xD;
      Biomarkers would help determine the effectiveness of therapies in slowing or stopping PD&#xD;
      progression, and accelerate the pace of research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early in the course of Parkinson's disease, a small dose of levodopa (L-DOPA) provides&#xD;
      benefit for many hours. The body responds as if the levodopa in the plasma filled a reservoir&#xD;
      and then slowly leaked out to produce benefit. With disease progression, even though the same&#xD;
      amount of levodopa circulates in the blood, the benefit wears off much faster, as if the&#xD;
      reservoir had become leakier. This wearing off of benefit can be characterized by a single&#xD;
      number, the effect site rate constant Ke. On average, patients with more severe disease and&#xD;
      longer disease duration have a larger (&quot;leakier&quot;) Ke when the response to drug is measured&#xD;
      using clinical features like tapping speed. Unfortunately, clinical measurements are&#xD;
      influenced by confounding factors such as patient fatigue and comfort. A direct, objective&#xD;
      brain measure of response to levodopa may improve the reliability of this measurement.&#xD;
      Fortunately, we can assess the effect of levodopa on the brain directly, using an MRI machine&#xD;
      to measure blood flow in different parts of the brain. For instance, the midbrain has a&#xD;
      robust blood flow response to a single, clinically sensible dose of levodopa. This study's&#xD;
      goal is to validate MRI measurement of Ke in the brain as an objective, quantitative measure&#xD;
      of disease severity in PD. We will do this by comparing MRI-based Ke values from people with&#xD;
      PD across a wide range of disease duration and severity. In a subgroup of participants, we&#xD;
      will do this measurement twice, once before treatment and once after 6 weeks of treatment&#xD;
      with carbidopa-levodopa (Sinemet® and other brand names).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Actual">October 19, 2019</completion_date>
  <primary_completion_date type="Actual">October 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants receive oral carbidopa before, and i.v. levodopa during brain imaging, to measure regional cerebral blood flow responses to levodopa.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ke measured by phMRI</measure>
    <time_frame>2 hours</time_frame>
    <description>Effect site rate constant measured by serum levodopa concentrations and regional cerebral blood flow. Note, there are no outcome measures relevant to clinical care. This is not a placebo-controlled treatment study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effect ratings</measure>
    <time_frame>2 hours</time_frame>
    <description>Nausea/vomiting, sleepiness, dizziness or lightheadedness, and overall feeling poorly or well, are each measured on a horizontal visual analog scale before and at the end of the i.v. levodopa infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>PD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A broad range of Parkinson's disease severity and disease duration. Some subjects will not be treated currently with levodopa, and thus likely will be early in the disease process.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa</intervention_name>
    <description>At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the &quot;final dose&quot; described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.&#xD;
Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above.</description>
    <arm_group_label>PD Group</arm_group_label>
    <other_name>Carbidopa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40-79 at screening&#xD;
&#xD;
          -  Meet accepted diagnostic criteria for Parkinson disease&#xD;
&#xD;
        Exclusion Criteria: Key exclusion criteria:&#xD;
&#xD;
          -  Deep brain stimulator (DBS)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients taking a dopamine antagonist (like quetiapine) or dopamine partial agonist&#xD;
             (like aripiprazole)&#xD;
&#xD;
          -  Metal in the head or eye, or other contraindication to MRI&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Serious neurologic disease other than PD&#xD;
&#xD;
          -  Head trauma with loss of consciousness for more than 5 minutes&#xD;
&#xD;
          -  Severe or unstable systemic illness&#xD;
&#xD;
          -  Certain psychiatric illnesses (dementia, psychosis, current major depression)&#xD;
&#xD;
          -  Current alcohol use disorder&#xD;
&#xD;
          -  Subjects who feel that going without nicotine for 3-4 hours would be uncomfortable&#xD;
&#xD;
          -  Currently taking an extended-release formulation of a dopamine agonist (like Mirapex&#xD;
             ER or Requip XL)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin J Black, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine, Movement Disorders Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Black KJ, Carl JL, Hartlein JM, Warren SL, Hershey T, Perlmutter JS. Rapid intravenous loading of levodopa for human research: clinical results. J Neurosci Methods. 2003 Jul 15;127(1):19-29.</citation>
    <PMID>12865145</PMID>
  </reference>
  <reference>
    <citation>Siddiqi SH, Abraham NK, Geiger CL, Karimi M, Perlmutter JS, Black KJ. The Human Experience with Intravenous Levodopa. Front Pharmacol. 2016 Jan 6;6:307. doi: 10.3389/fphar.2015.00307. eCollection 2015. Review.</citation>
    <PMID>26779024</PMID>
  </reference>
  <reference>
    <citation>Koller JM, Vachon MJ, Bretthorst GL, Black KJ. Rapid Quantitative Pharmacodynamic Imaging with Bayesian Estimation. Front Neurosci. 2016 Apr 8;10:144. doi: 10.3389/fnins.2016.00144. eCollection 2016.</citation>
    <PMID>27092045</PMID>
  </reference>
  <reference>
    <citation>Black KJ, Acevedo HK, Koller JM. Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease. Front Neurol. 2020 May 6;11:370. doi: 10.3389/fneur.2020.00370. eCollection 2020.</citation>
    <PMID>32477245</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kevin J. Black, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>PD</keyword>
  <keyword>levodopa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will publicly share a fully anonymized set of linked data from this study. No protected health information (PHI) will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>36 months after completion of last participant</ipd_time_frame>
    <ipd_access_criteria>Public</ipd_access_criteria>
    <ipd_url>https://osf.io/ezb6n/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03205956/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

